Altamira Therapeutics Reports Pricing Of Up To $12M Public Offering; $4M Upfront With Up To Additional $8M Of Aggregate Gross Proceeds Upon Exercise Of Milestone-linked Warrants
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics has announced a public offering priced at $0.72 per share, aiming to raise up to $12 million. The offering includes 5.55 million common shares and warrants, with $4 million upfront and potential additional $8 million from milestone-linked warrants.
September 17, 2024 | 9:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Altamira Therapeutics (CYTO) is conducting a public offering to raise up to $12 million, with an initial $4 million and potential $8 million from warrants. This could impact CYTO's stock price due to dilution and investor sentiment.
The public offering involves issuing new shares, which can lead to stock dilution, potentially affecting the stock price negatively. The offering's success and the exercise of warrants could further influence investor sentiment and stock performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100